WO2024245220 - METHOD AND COMPOSITION TO REDUCE OR INHIBIT ADVANCED GLYCATION END-PRODUCTS
National phase entry is expected:
Publication Number
WO/2024/245220
Publication Date
05.12.2024
International Application No.
PCT/CN2024/095694
International Filing Date
28.05.2024
Title **
[English]
METHOD AND COMPOSITION TO REDUCE OR INHIBIT ADVANCED GLYCATION END-PRODUCTS
[French]
PROCÉDÉ ET COMPOSITION POUR RÉDUIRE OU INHIBER DES PRODUITS FINAUX DE GLYCATION AVANCÉS
Applicants **
NANJING NUTRABUILDING BIO-TECH CO., LTD.
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
Inventors
YI, Ronghua
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
LIAO, Kylin
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
WELLS, Shawn
Room 1805, Building 1, No. 270 Jiqingmen Street, Gulou District
Nanjing, Jiangsu 210017, CN
Priority Data
PCT/CN2023/097046
30.05.2023
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
CNIPA
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1581 | |
| EPO | Filing, Examination | 12500 | |
| Japan | Filing | 533 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 5835 |
Total: 21024 USD
Abstract[English]
Novel methods for reducing or inhibiting advanced glycation end products (AGEs) in a subject, comprising administration to the subject a composition comprising an effective amount of tetrahydrocurcumin or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof; and an effective amount of ergothioneine or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof. A composition comprising an effective amount of tetrahydrocurcumin or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof; and an effective amount of ergothioneine or a pharmaceutically acceptable salt, acid, ester, analog or derivative thereof, for reducing or inhibiting advanced glycation end products (AGEs) in a subject.[French]
L'invention concerne des nouvelles méthodes de réduction ou d'inhibition de produits de glycation avancée (AGE, « advanced glycation product ») chez un patient, consistant en l'administration, au patient, d'une composition contenant une quantité efficace de tétrahydrocurcumine ou d'un sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptable associé ; et une quantité efficace d'ergothionéine ou d'un sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptable associé. L'invention concerne en outre une composition contenant une quantité efficace de tétrahydrocurcumine ou d'un sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptable associé ; et une quantité efficace d'ergothionéine ou d'un sel, acide, ester, analogue ou dérivé pharmaceutiquement acceptable associé, afin de réduire ou d'inhiber des produits de glycation avancée (AGE) chez un patient.